Cargando…

Biomaterial‐based gene therapy

Gene therapy, a medical approach that involves the correction or replacement of defective and abnormal genes, plays an essential role in the treatment of complex and refractory diseases, such as hereditary diseases, cancer, and rheumatic immune diseases. Nucleic acids alone do not easily enter the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yi, Gao, Yijun, He, Liming, Fang, Bairong, Ge, Wenhui, Yang, Pu, Ju, Yikun, Xie, Xiaoyan, Lei, Lanjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239531/
https://www.ncbi.nlm.nih.gov/pubmed/37284583
http://dx.doi.org/10.1002/mco2.259
_version_ 1785053506651029504
author Yu, Yi
Gao, Yijun
He, Liming
Fang, Bairong
Ge, Wenhui
Yang, Pu
Ju, Yikun
Xie, Xiaoyan
Lei, Lanjie
author_facet Yu, Yi
Gao, Yijun
He, Liming
Fang, Bairong
Ge, Wenhui
Yang, Pu
Ju, Yikun
Xie, Xiaoyan
Lei, Lanjie
author_sort Yu, Yi
collection PubMed
description Gene therapy, a medical approach that involves the correction or replacement of defective and abnormal genes, plays an essential role in the treatment of complex and refractory diseases, such as hereditary diseases, cancer, and rheumatic immune diseases. Nucleic acids alone do not easily enter the target cells due to their easy degradation in vivo and the structure of the target cell membranes. The introduction of genes into biological cells is often dependent on gene delivery vectors, such as adenoviral vectors, which are commonly used in gene therapy. However, traditional viral vectors have strong immunogenicity while also presenting a potential infection risk. Recently, biomaterials have attracted attention for use as efficient gene delivery vehicles, because they can avoid the drawbacks associated with viral vectors. Biomaterials can improve the biological stability of nucleic acids and the efficiency of intracellular gene delivery. This review is focused on biomaterial‐based delivery systems in gene therapy and disease treatment. Herein, we review the recent developments and modalities of gene therapy. Additionally, we discuss nucleic acid delivery strategies, with a focus on biomaterial‐based gene delivery systems. Furthermore, the current applications of biomaterial‐based gene therapy are summarized.
format Online
Article
Text
id pubmed-10239531
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102395312023-06-05 Biomaterial‐based gene therapy Yu, Yi Gao, Yijun He, Liming Fang, Bairong Ge, Wenhui Yang, Pu Ju, Yikun Xie, Xiaoyan Lei, Lanjie MedComm (2020) Reviews Gene therapy, a medical approach that involves the correction or replacement of defective and abnormal genes, plays an essential role in the treatment of complex and refractory diseases, such as hereditary diseases, cancer, and rheumatic immune diseases. Nucleic acids alone do not easily enter the target cells due to their easy degradation in vivo and the structure of the target cell membranes. The introduction of genes into biological cells is often dependent on gene delivery vectors, such as adenoviral vectors, which are commonly used in gene therapy. However, traditional viral vectors have strong immunogenicity while also presenting a potential infection risk. Recently, biomaterials have attracted attention for use as efficient gene delivery vehicles, because they can avoid the drawbacks associated with viral vectors. Biomaterials can improve the biological stability of nucleic acids and the efficiency of intracellular gene delivery. This review is focused on biomaterial‐based delivery systems in gene therapy and disease treatment. Herein, we review the recent developments and modalities of gene therapy. Additionally, we discuss nucleic acid delivery strategies, with a focus on biomaterial‐based gene delivery systems. Furthermore, the current applications of biomaterial‐based gene therapy are summarized. John Wiley and Sons Inc. 2023-06-03 /pmc/articles/PMC10239531/ /pubmed/37284583 http://dx.doi.org/10.1002/mco2.259 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Yu, Yi
Gao, Yijun
He, Liming
Fang, Bairong
Ge, Wenhui
Yang, Pu
Ju, Yikun
Xie, Xiaoyan
Lei, Lanjie
Biomaterial‐based gene therapy
title Biomaterial‐based gene therapy
title_full Biomaterial‐based gene therapy
title_fullStr Biomaterial‐based gene therapy
title_full_unstemmed Biomaterial‐based gene therapy
title_short Biomaterial‐based gene therapy
title_sort biomaterial‐based gene therapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239531/
https://www.ncbi.nlm.nih.gov/pubmed/37284583
http://dx.doi.org/10.1002/mco2.259
work_keys_str_mv AT yuyi biomaterialbasedgenetherapy
AT gaoyijun biomaterialbasedgenetherapy
AT heliming biomaterialbasedgenetherapy
AT fangbairong biomaterialbasedgenetherapy
AT gewenhui biomaterialbasedgenetherapy
AT yangpu biomaterialbasedgenetherapy
AT juyikun biomaterialbasedgenetherapy
AT xiexiaoyan biomaterialbasedgenetherapy
AT leilanjie biomaterialbasedgenetherapy